🚀 VC round data is live in beta, check it out!
Crescent Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Crescent Biopharma and similar public comparables like Neurogene, Hansa Biopharma, Northwest Biotherapeutics, Sutro Biopharma and more.
Crescent Biopharma Overview
About Crescent Biopharma
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Founded
2024
HQ
Employees
33
Website
Sectors
Financials (LTM)
EV
$137M
Crescent Biopharma Financials
Crescent Biopharma reported last 12-month revenue of $10M.
In the same LTM period, Crescent Biopharma generated $10M in gross profit and had net loss of ($148M).
Revenue (LTM)
Crescent Biopharma P&L
In the most recent fiscal year, Crescent Biopharma reported revenue of $11M and EBITDA of ($150M).
Crescent Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $11M | XXX | XXX | XXX |
| Gross Profit | $10M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($150M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1380%) | XXX | XXX | XXX |
| EBIT Margin | (1525%) | XXX | (1390%) | XXX | XXX | XXX |
| Net Profit | ($148M) | XXX | ($154M) | XXX | XXX | XXX |
| Net Margin | (1546%) | XXX | (1420%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Crescent Biopharma Stock Performance
Crescent Biopharma has current market cap of $345M, and enterprise value of $137M.
Market Cap Evolution
Crescent Biopharma's stock price is $11.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $137M | $345M | 0.0% | XXX | XXX | XXX | $-5.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCrescent Biopharma Valuation Multiples
Crescent Biopharma trades at 14.3x EV/Revenue multiple, and (0.9x) EV/EBITDA.
EV / Revenue (LTM)
Crescent Biopharma Financial Valuation Multiples
As of March 7, 2026, Crescent Biopharma has market cap of $345M and EV of $137M.
Equity research analysts estimate Crescent Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Crescent Biopharma has a P/E ratio of (2.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $345M | XXX | $345M | XXX | XXX | XXX |
| EV (current) | $137M | XXX | $137M | XXX | XXX | XXX |
| EV/Revenue | 14.3x | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.9x) | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 14.3x | XXX | — | XXX | XXX | XXX |
| P/E | (2.3x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Crescent Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Crescent Biopharma Margins & Growth Rates
Crescent Biopharma's revenue in the last 12 month declined by (58%).
Crescent Biopharma's revenue per employee in the last FY averaged $0.3M.
Crescent Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (58%) | XXX | (64%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1380%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 270% | XXX | 234% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1337% | XXX | 1273% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1508% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Crescent Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Neurogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Hansa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Northwest Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sutro Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Avalo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Crescent Biopharma M&A Activity
Crescent Biopharma acquired XXX companies to date.
Last acquisition by Crescent Biopharma was on XXXXXXXX, XXXXX. Crescent Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Crescent Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCrescent Biopharma Investment Activity
Crescent Biopharma invested in XXX companies to date.
Crescent Biopharma made its latest investment on XXXXXXXX, XXXXX. Crescent Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Crescent Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Crescent Biopharma
| When was Crescent Biopharma founded? | Crescent Biopharma was founded in 2024. |
| Where is Crescent Biopharma headquartered? | Crescent Biopharma is headquartered in United States. |
| How many employees does Crescent Biopharma have? | As of today, Crescent Biopharma has over 33 employees. |
| Who is the CEO of Crescent Biopharma? | Crescent Biopharma's CEO is Joshua T. Brumm. |
| Is Crescent Biopharma publicly listed? | Yes, Crescent Biopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Crescent Biopharma? | Crescent Biopharma trades under CBIO ticker. |
| When did Crescent Biopharma go public? | Crescent Biopharma went public in 2025. |
| Who are competitors of Crescent Biopharma? | Crescent Biopharma main competitors are Neurogene, Hansa Biopharma, Northwest Biotherapeutics, Sutro Biopharma. |
| What is the current market cap of Crescent Biopharma? | Crescent Biopharma's current market cap is $345M. |
| What is the current revenue of Crescent Biopharma? | Crescent Biopharma's last 12 months revenue is $10M. |
| What is the current revenue growth of Crescent Biopharma? | Crescent Biopharma revenue growth (NTM/LTM) is (58%). |
| What is the current EV/Revenue multiple of Crescent Biopharma? | Current revenue multiple of Crescent Biopharma is 14.3x. |
| Is Crescent Biopharma profitable? | No, Crescent Biopharma is not profitable. |
| What is the current net income of Crescent Biopharma? | Crescent Biopharma's last 12 months net income is ($148M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.